Robert Bayer
Cytel
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert Bayer.
Journal of Clinical Investigation | 1992
Michael S. Mulligan; Margaret J. Polley; Robert Bayer; Michael Nunn; James C. Paulson; Peter A. Ward
Rapid translocation of P-selectin (GMP-140) from cytoplasmic granules to the cell membrane of endothelial cells promotes adhesive interactions with neutrophils which, when activated, damage the endothelium. The role of P-selectin in lung vascular endothelial injury in rats after systemic activation of complement by intravenous infusion of cobra venom factor has been assessed. Within 5-10 min after cobra venom factor infusion, the pulmonary vasculature demonstrated immunohistochemical expression of an epitope that reacts with anti-human P-selectin. Monoclonal antibody to human P-selectin blocked in vitro adherence of rat or human platelets (activated with thrombin) to neutrophils and was demonstrated to react with thrombin-activated rat platelets. The antibody did not react with rat neutrophils. In vivo, the antibody had strongly protective effects against cobra venom factor-induced pulmonary vascular injury as determined by permeability changes and hemorrhage. In parallel, lung myeloperoxidase content was greatly reduced and, by transmission electron microscopy, there was markedly diminished adherence of neutrophils to the pulmonary vascular endothelium and much diminished injury of endothelial cells, as defined by hemorrhage. These data indicate that anti-human P-selectin reacts with a pulmonary vascular antigen in rats and that this antigen is essential for the full expression of lung injury.
Journal of Clinical Investigation | 1995
M. L. Phillips; B R Schwartz; A Etzioni; Robert Bayer; H D Ochs; James C. Paulson; J M Harlan
We have previously reported a newly discovered congenital disorder of neutrophil adhesion, leukocyte adhesion deficiency syndrome type 2 (LAD II). The clinical manifestations of this syndrome are similar to those seen in the classic leukocyte adhesion deficiency syndrome, now designated type 1 (LAD I), but the two syndromes differ in the molecular basis of their adhesion defects. LAD I is caused by a deficiency in the CD18 integrin adhesion molecules while LAD II patients are deficient in expression of sialyl-Lewis X (SLeX), a carbohydrate ligand for selectins. In this report we demonstrate that neutrophils from a LAD II patient bind minimally or not at all to recombinant E-selectin, purified platelet P-selectin, or P-selectin expressed on histamine-activated human umbilical vein endothelial cells, but have normal levels of L-selectin and CD11b/CD18 integrin, and adhere to and migrate across endothelium when CD11b/CD18 is activated. We compare LAD I and LAD II patient neutrophil function in vitro, demonstrating that integrin and selectin adhesion molecules have distinct but interdependent roles in neutrophil adhesion during an inflammatory response.
Archive | 1998
James C. Paulson; Robert Bayer; Eric Sjoberg
Archive | 1993
Robert W. Chestnut; Margaret J. Polley; James C. Paulson; S. Tarran Jones; Jose W. Saldanha; Mary Margaret Bendig; Michael Kriegler; Carl Perez; Robert Bayer; Michael Nunn
Archive | 1997
R W Chesnut; Margaret J. Polley; James C. Paulson; S. Tarran Jones; Jose W. Saldanha; Mary Margaret Bendig; Michael Kriegler; Carl Perez; Robert Bayer; Michael Nunn
Archive | 1998
Robert Bayer; James C. Paulson; Eric Sjoberg
Archive | 1998
James C. Paulson; Robert Bayer; Eric Sjoberg
Archive | 1998
Robert Bayer; James C. Paulson; Eric Sjoberg
Archive | 1995
Robert W. Chesnut; Margaret J. Polley; James C. Paulson; S. Tarran Jones; Jose Saldanha; Mary M. Bendig; Michael Kriegler; Carl Perez; Robert Bayer; Michael Nunn
Archive | 1995
Robert W. Chesnut; Margaret J. Polley; James C. Paulson; S. Tarran Jones; Jose Saldanha; Mary M. Bendig; Michael Kriegler; Carl Perez; Robert Bayer; Michael Nunn